• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.2840 -0.0177 (-5.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why ↗
April 23, 2025
Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protection technology. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
April 23, 2025
 
Via Benzinga
News headline image
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
April 23, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
April 23, 2025
 
Via Benzinga
News headline image
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
February 05, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
January 22, 2025
Via ACCESS Newswire
News headline image
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views ↗
April 23, 2025
 
Via Benzinga
News headline image
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results ↗
April 23, 2025
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
April 23, 2025
 
Via Benzinga
News headline image
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
April 23, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled ↗
April 15, 2025
The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed. 
Via Stocktwits
Topics Government
News headline image
Ensysce Biosciences Issues Annual Shareholder Letter
January 08, 2025
Via ACCESSWIRE
News headline image
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
December 10, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
April 15, 2025
 
Via Benzinga
News headline image
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
April 15, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
April 10, 2025
 
Via Benzinga
News headline image
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 31, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
December 04, 2024
Via ACCESSWIRE
News headline image
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
November 26, 2024
Via ACCESSWIRE
News headline image
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
March 18, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
March 13, 2025
 
Via Benzinga
News headline image
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
March 05, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Regains Full Compliance with Nasdaq
December 23, 2024
Via ACCESSWIRE
News headline image
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
December 04, 2024
 
Via Benzinga
News headline image
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
November 12, 2024
Via ACCESSWIRE
News headline image
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
December 03, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
November 13, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
November 07, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
November 07, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap